← All trials
NCT05599919
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2021
- Primary completion
- Jan 31, 2022
- Completion date
- Feb 2, 2022
- First posted
- Oct 31, 2022
- Last posted
- Oct 31, 2022
- Enrollment
- 306
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sanotize Research and Development Corp.Lead sponsor
- Glenmark PharmaceuticalsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.